DE69423402T2 - Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten - Google Patents

Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten

Info

Publication number
DE69423402T2
DE69423402T2 DE69423402T DE69423402T DE69423402T2 DE 69423402 T2 DE69423402 T2 DE 69423402T2 DE 69423402 T DE69423402 T DE 69423402T DE 69423402 T DE69423402 T DE 69423402T DE 69423402 T2 DE69423402 T2 DE 69423402T2
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
compositions containing
hybrid alpha
stable pharmaceutical
alpha interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69423402T
Other languages
English (en)
Other versions
DE69423402D1 (de
Inventor
Nicholas Lowther
John Douglas Allen
Colin Howes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Application granted granted Critical
Publication of DE69423402D1 publication Critical patent/DE69423402D1/de
Publication of DE69423402T2 publication Critical patent/DE69423402T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE69423402T 1993-08-13 1994-08-10 Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten Expired - Fee Related DE69423402T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69423402D1 DE69423402D1 (de) 2000-04-20
DE69423402T2 true DE69423402T2 (de) 2000-08-03

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69423402T Expired - Fee Related DE69423402T2 (de) 1993-08-13 1994-08-10 Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten

Country Status (19)

Country Link
US (1) US5609868A (de)
EP (1) EP0641567B1 (de)
JP (1) JP3745395B2 (de)
KR (1) KR100351495B1 (de)
AT (1) ATE190498T1 (de)
AU (1) AU679233B2 (de)
CA (1) CA2129921C (de)
CY (1) CY2230B1 (de)
DE (1) DE69423402T2 (de)
DK (1) DK0641567T3 (de)
ES (1) ES2144034T3 (de)
FI (1) FI111222B (de)
GR (1) GR3033239T3 (de)
HU (1) HU224613B1 (de)
IL (1) IL110566A (de)
NO (1) NO315843B1 (de)
NZ (1) NZ264218A (de)
PT (1) PT641567E (de)
TW (1) TW249202B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
EA002754B1 (ru) * 1996-12-24 2002-08-29 Байоджен, Инк. Устойчивые жидкие составы интерферона
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
WO2007000769A2 (en) * 2005-06-29 2007-01-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
PT82249B (en) * 1985-03-25 1988-01-07 Schering Corp Process for preparing stable gamma-interferon formulations
EP0205404B1 (de) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid-Interferone
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.

Also Published As

Publication number Publication date
CY2230B1 (en) 2003-04-18
NZ264218A (en) 1995-07-26
DE69423402D1 (de) 2000-04-20
AU679233B2 (en) 1997-06-26
TW249202B (de) 1995-06-11
FI943705A0 (fi) 1994-08-10
GR3033239T3 (en) 2000-09-29
DK0641567T3 (da) 2000-08-14
IL110566A (en) 1999-12-22
EP0641567A1 (de) 1995-03-08
HUT68692A (en) 1995-07-28
FI943705A (fi) 1995-02-14
ES2144034T3 (es) 2000-06-01
KR950005325A (ko) 1995-03-20
NO942983L (no) 1995-02-14
JP3745395B2 (ja) 2006-02-15
KR100351495B1 (ko) 2003-02-19
FI111222B (fi) 2003-06-30
CA2129921A1 (en) 1995-02-14
PT641567E (pt) 2000-08-31
IL110566A0 (en) 1995-01-24
US5609868A (en) 1997-03-11
NO315843B1 (no) 2003-11-03
CA2129921C (en) 2006-12-05
EP0641567B1 (de) 2000-03-15
HU224613B1 (hu) 2005-11-28
HU9402356D0 (en) 1994-10-28
AU6893994A (en) 1995-02-23
NO942983D0 (no) 1994-08-12
JPH07145070A (ja) 1995-06-06
ATE190498T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
ES2144421T3 (es) Nuevo derivado tetrapeptidico.
DE69319440T2 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
DE69423402D1 (de) Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2146606T3 (es) Metodo para limpiar alfombras.
EP0974347A4 (de) Antivirale mittel
ATE103166T1 (de) Haarbehandlungszusammensetzung.
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
ES2106680B1 (es) Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
MA23133A1 (fr) Derives d'acide d'acyloxyhexanoique .
FI903701A0 (fi) Reninhaemmande amino-oligohydroxiderivat.
ES2107562T3 (es) Amidas de acidos alfa-aril-alfa-hidroxi-beta-imidazolinil-propanoicos.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
DE59308331D1 (de) Verfahren zur Herstellung von 1-unsubstituierten 3-Aminopyrrolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee